Ibrance and Vinorelbine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ibrance (palbociclib) and Vinorelbine (vinorelbine). Common drug interactions include malignant neoplasm progression among females.

The phase IV clinical study analyzes what interactions people have when they take Ibrance and Vinorelbine. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

What is Vinorelbine?

Vinorelbine has active ingredients of vinorelbine. eHealthMe is studying from 6,381 Vinorelbine users. Check the latest studies of Vinorelbine.

On Jul, 08, 2026

17 people who take Ibrance and Vinorelbine together, and have interactions are studied.

Ibrance and Vinorelbine drug interactions.

What are the common drug interactions of Ibrance and Vinorelbine, by gender? *:

female:

Malignant neoplasm progression (cancer tumour came back)
Neutropenia (an abnormally low number of neutrophils)
Decreased appetite
Drug intolerance (drug sensitivity)
Fractured sacrum
General physical health deterioration (weak health status)
Hepatic lesion
Keratopathy (noninflammatory disease of the cornea)
Lymphangiosis carcinomatosa (inflammation of the lymph vessels can lead to cancer)
Palpitations (feelings or sensations that your heart is pounding or racing)

male:

n/a

What are the common drug interactions of Ibrance and Vinorelbine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Neoplasm progression (growth of tumour)

20-29:

Malignant neoplasm progression (cancer tumour came back)
Metastases to bone (cancer spreads to bone)
Metastases to central nervous system (cancer spreads to central nervous system)
Metastases to lymph nodes (cancer spreads to lymph node)
Neutropenia (an abnormally low number of neutrophils)
White blood cell count decreased

30-39:

n/a

40-49:

n/a

50-59:

Asthenia (weakness)
Breast cancer
Breast cancer metastatic
Drug intolerance (drug sensitivity)
Fatigue (feeling of tiredness)
Malignant neoplasm progression (cancer tumour came back)
Neuropathy peripheral (surface nerve damage)
Neutropenia (an abnormally low number of neutrophils)
Pain
Tumour marker increased

60+:

Malignant neoplasm progression (cancer tumour came back)
Abdominal pain upper
Hepatic lesion
Keratopathy (noninflammatory disease of the cornea)
Lymphangiosis carcinomatosa (inflammation of the lymph vessels can lead to cancer)
Metastases to bone (cancer spreads to bone)
Metastases to liver (cancer spreads to liver)
Neutropenia (an abnormally low number of neutrophils)
Palpitations (feelings or sensations that your heart is pounding or racing)
Pleural effusion (water on the lungs)

What are the existing conditions these people have? *

Breast Cancer: 8 people, 47.06%
Breast Cancer Metastatic: 4 people, 23.53%
Pain: 2 people, 11.76%
Neuropathy Peripheral (surface nerve damage): 2 people, 11.76%
Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 1 person, 5.88%
Breast Cancer Female: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrance and Vinorelbine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously